Metharbital: Difference between revisions
m (Protected "Metharbital": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
Rabin Bista (talk | contribs) No edit summary |
||
(One intermediate revision by the same user not shown) | |||
Line 1: | Line 1: | ||
{{ | {{Drugbox | ||
| IUPAC_name = 5,5-diethyl-1- | | verifiedrevid = 459493742 | ||
| image = Metharbital.png | | IUPAC_name = 5,5-diethyl-1-methylpyrimidine-2,4,6(1''H'',3''H'',5''H'')-trione | ||
| image = Metharbital Wiki Str.png | |||
| width = 141 | | width = 141 | ||
<!--Clinical data--> | |||
| tradename = | |||
| Drugs.com = {{drugs.com|monograph|luminal}} | |||
| pregnancy_category = | |||
| legal_status = | |||
| routes_of_administration = | |||
<!--Pharmacokinetic data--> | |||
| bioavailability = | |||
| protein_bound = | |||
| metabolism = | |||
| elimination_half-life = | |||
<!--Identifiers--> | |||
| CASNo_Ref = {{cascite|correct|CAS}} | |||
| CAS_number_Ref = {{cascite|correct|??}} | |||
| CAS_number = 50-11-3 | | CAS_number = 50-11-3 | ||
| ATC_prefix = N03 | | ATC_prefix = N03 | ||
| ATC_suffix = AA30 | | ATC_suffix = AA30 | ||
| ATC_supplemental = | | ATC_supplemental = | ||
| PubChem = 4099 | | PubChem = 4099 | ||
| DrugBank = | | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | ||
| C=9 | H=14 | N=2 | O=3 | | DrugBank = DB00463 | ||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | |||
| ChemSpiderID = 3957 | |||
| UNII_Ref = {{fdacite|correct|FDA}} | |||
| UNII = 02OS7K758T | |||
| KEGG_Ref = {{keggcite|correct|kegg}} | |||
| KEGG = D01382 | |||
| ChEMBL_Ref = {{ebicite|correct|EBI}} | |||
| ChEMBL = 450 | |||
<!--Chemical data--> | |||
| C=9 | H=14 | N=2 | O=3 | |||
| molecular_weight = 198.219 g/mol | | molecular_weight = 198.219 g/mol | ||
| | | smiles = O=C1N(C(=O)NC(=O)C1(CC)CC)C | ||
| | | InChI = 1/C9H14N2O3/c1-4-9(5-2)6(12)10-8(14)11(3)7(9)13/h4-5H2,1-3H3,(H,10,12,14) | ||
| | | InChIKey = FWJKNZONDWOGMI-UHFFFAOYAX | ||
| | | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | ||
| | | StdInChI = 1S/C9H14N2O3/c1-4-9(5-2)6(12)10-8(14)11(3)7(9)13/h4-5H2,1-3H3,(H,10,12,14) | ||
| | | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | ||
| | | StdInChIKey = FWJKNZONDWOGMI-UHFFFAOYSA-N | ||
}} | }} | ||
'''Metharbital''' was patented in 1905 by [[Hermann Emil Fischer|Emil Fischer]] working for [[Merck KGaA|Merck]]<ref>US Patent 782742</ref> | __NOTOC__ | ||
{{SI}} | |||
{{CMG}} | |||
== Overview == | |||
'''Metharbital''' was patented in 1905 by [[Hermann Emil Fischer|Emil Fischer]] working for [[Merck KGaA|Merck]].<ref>US Patent 782742</ref> It was marketed as '''Gemonil''' by [[Abbott Laboratories]]. It is a [[barbiturate]] [[anticonvulsant]], used in the treatment of [[epilepsy]]. It has similar properties to [[phenobarbital]]. | |||
== History == | == History == | ||
Line 25: | Line 60: | ||
* '''1952''' Gemonil was introduced by Abbott Laboratories. | * '''1952''' Gemonil was introduced by Abbott Laboratories. | ||
* '''1990''' Abbott stopped marketing. | * '''1990''' Abbott stopped marketing. | ||
==Synthesis== | |||
[[File:Metharbital syn.png|center|700px<ref>A. Halpern, J.W. Jones, J. Am. Pharm. Assoc., 38, 352 (1949).</ref><ref>{{Cite doi|10.1021/ja01104a030}}</ref> {{US patent|782742}}]] | |||
In an interesting variation on this theme (cf [[hexobarbital]]), the bis acid chloride of [[diethylmalonate]] ('''1''') is condensed with the O-methyl ether of urea ('''2''', Methyl carbamimidate<ref>http://www.chemspider.com/Chemical-Structure.68069.html?rid=81ad3137-afb0-456a-8c9f-d6c73ada4966</ref>) to afford the imino ether of the barbituric acid ('''3'''). Heating this ether at 200°C results in O to N migration of the methyl group and formation of metharbital '''4'''. | |||
==References== | ==References== | ||
{{Reflist|2}} | |||
* ''The Treatment of Epilepsy 2nd Ed'' by S. D. Shorvon (Editor), David R. Fish (Editor), Emilio Perucca (Editor), W. Edwin Dodson (Editor). Published by Blackwell 2004. ISBN 0-632-06046-8 | * ''The Treatment of Epilepsy 2nd Ed'' by S. D. Shorvon (Editor), David R. Fish (Editor), Emilio Perucca (Editor), W. Edwin Dodson (Editor). Published by Blackwell 2004. ISBN 0-632-06046-8 | ||
* ''The Medical Treatment of Epilepsy'' by Stanley R Resor. Published by Marcel Dekker (1991). ISBN 0-8247-8549-5. | * ''The Medical Treatment of Epilepsy'' by Stanley R Resor. Published by Marcel Dekker (1991). ISBN 0-8247-8549-5. | ||
* [http:// | * [http://ctdbase.org/detail.go?type=chem&acc=C084822 The Comparative Toxicogenomics Database: Metharbital] | ||
<references/> | <references/> | ||
{{GABAAR PAMs}} | |||
[[Category:drug]] | |||
[[Category:Barbiturates]] | [[Category:Barbiturates]] | ||
[[Category:Anticonvulsants]] | [[Category:Anticonvulsants]] | ||
[[Category:Pyrimidinediones]] | |||
[[Category:Imides]] | |||
[[Category:GABAA receptor positive allosteric modulators]] | |||
{{ | {{anticonvulsant-stub}} | ||
Latest revision as of 13:14, 14 April 2015
Clinical data | |
---|---|
AHFS/Drugs.com | Monograph |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C9H14N2O3 |
Molar mass | 198.219 g/mol |
3D model (JSmol) | |
| |
| |
(verify) |
WikiDoc Resources for Metharbital |
Articles |
---|
Most recent articles on Metharbital Most cited articles on Metharbital |
Media |
Powerpoint slides on Metharbital |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Metharbital at Clinical Trials.gov Clinical Trials on Metharbital at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Metharbital
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Metharbital Discussion groups on Metharbital Patient Handouts on Metharbital Directions to Hospitals Treating Metharbital Risk calculators and risk factors for Metharbital
|
Healthcare Provider Resources |
Causes & Risk Factors for Metharbital |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Metharbital was patented in 1905 by Emil Fischer working for Merck.[1] It was marketed as Gemonil by Abbott Laboratories. It is a barbiturate anticonvulsant, used in the treatment of epilepsy. It has similar properties to phenobarbital.
History
- 1952 Gemonil was introduced by Abbott Laboratories.
- 1990 Abbott stopped marketing.
Synthesis
In an interesting variation on this theme (cf hexobarbital), the bis acid chloride of diethylmalonate (1) is condensed with the O-methyl ether of urea (2, Methyl carbamimidate[4]) to afford the imino ether of the barbituric acid (3). Heating this ether at 200°C results in O to N migration of the methyl group and formation of metharbital 4.
References
- ↑ US Patent 782742
- ↑ A. Halpern, J.W. Jones, J. Am. Pharm. Assoc., 38, 352 (1949).
- ↑ Template:Cite doi
- ↑ http://www.chemspider.com/Chemical-Structure.68069.html?rid=81ad3137-afb0-456a-8c9f-d6c73ada4966
- The Treatment of Epilepsy 2nd Ed by S. D. Shorvon (Editor), David R. Fish (Editor), Emilio Perucca (Editor), W. Edwin Dodson (Editor). Published by Blackwell 2004. ISBN 0-632-06046-8
- The Medical Treatment of Epilepsy by Stanley R Resor. Published by Marcel Dekker (1991). ISBN 0-8247-8549-5.
- The Comparative Toxicogenomics Database: Metharbital
- Pages with script errors
- Template:drugs.com link with non-standard subpage
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Drugs with no legal status
- Drug
- Barbiturates
- Anticonvulsants
- Pyrimidinediones
- Imides
- GABAA receptor positive allosteric modulators
- Anticonvulsant stubs